Clinical Trials Browser

Phase 3 × Anemia × Thoracic × Clear all

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03776032 2018-12-20

A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

Phase 3 Completed

320 enrolled

Classical hematologyThoracic

Anemia, Lung Neoplasms

NCT00003600 2016-07-13

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Phase 3 Completed

344 enrolled

BreastClassical hematologyLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellThoracic

Anemia, Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Precancerous Conditions, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Phase 3 Completed

201 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy